An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Acorda Therapeutics (NASDAQ: ACOR) announced the launch of INBRIJA 33 mg (levodopa inhalation powder) by Esteve Pharmaceuticals in Spain, aimed at treating OFF episodes in adults with Parkinson's disease. Acorda will receive a significant double-digit percentage of the selling price under a supply agreement. The Spanish Ministry of Health estimates at least 160,000 people in Spain are affected by Parkinson's, with 10,000 new cases diagnosed each year. Esteve previously launched INBRIJA in Germany and is expanding commercialization efforts across Latin America and Europe.
Positive
Launch of INBRIJA in Spain increases product availability for Parkinson's patients.
Acorda receives significant revenue share from the sales of INBRIJA under the supply agreement.
Negative
None.
PEARL RIVER, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Esteve Pharmaceuticals, S.A. has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor. (1)
As previously announced, under the terms of the supply agreement with Esteve, Acorda will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product.
According to data from the White Paper on Parkinson's in Spain - published by the Ministry of Health, Social Services and Equality and co-published by the Spanish Parkinson's Federation - this chronic and progressive neurological disease affects at least 160,000 people in Spain. According to the Spanish Society of Neurology (SEN), about 10,000 new cases are diagnosed each year.(2)
“Today’s announcement is great news for people in Spain who are living with Parkinson’s and suffer from OFF periods. Esteve is a leader in commercializing central nervous system therapeutics in Spain. They will be educating neurologists about providing patients with the ability to treat their OFF periods on-demand with INBRIJA,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics.
Esteve launched INBRIJA in Germany in mid-2022. Acorda also previously announced an agreement with Biopas Laboratories to commercialize INBRIJA in the nine largest markets in Latin America, including Mexico and Brazil. Acorda is also in active discussions with additional companies for the rights to INBRIJA in other countries in Europe and other parts of the world.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
Forward-Looking Statements
This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market AMPYRA, INBRIJA or any other products under development; the COVID-19 pandemic, including related restrictions on in-person interactions and travel, and the potential for illness, quarantines and vaccine mandates affecting our management, employees or consultants or those that work for other companies we rely upon, could have a material adverse effect on our business operations or product sales; our ability to attract and retain key management and other personnel, or maintain access to expert advisors; our ability to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures; risks associated with the trading of our common stock; risks related to the successful implementation of our business plan, including the accuracy of its key assumptions; risks related to our corporate restructurings, including our ability to outsource certain operations, realize expected cost savings and maintain the workforce needed for continued operations; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA or AMPYRA to meet market demand; our reliance on third-party manufacturers for the timely production of commercial supplies of INBRIJA and AMPYRA; third-party payers (including governmental agencies) may not reimburse for the use of INBRIJA or AMPYRA at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and AMPYRA outside the U.S.; our ability to satisfy our obligations to distributors and collaboration partners outside the U.S. relating to commercialization and supply of INBRIJA and AMPYRA; competition for INBRIJA and AMPYRA, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of AMPYRA (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions because, among other reasons, acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the risk of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class-action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third-party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release, except as may be required by law.
What is the significance of Acorda Therapeutics' recent announcement regarding INBRIJA?
Acorda Therapeutics announced that Esteve Pharmaceuticals launched INBRIJA in Spain, providing a new treatment option for Parkinson's patients dealing with OFF episodes.
How will Acorda benefit from the launch of INBRIJA in Spain?
Acorda will receive a significant double-digit percentage of the selling price of INBRIJA sold in Spain, enhancing its revenue stream.
How many people are affected by Parkinson's disease in Spain according to Acorda's press release?
According to the press release, approximately 160,000 people in Spain are affected by Parkinson's disease, with 10,000 new cases diagnosed annually.
What other markets is Acorda targeting for INBRIJA?
Acorda is also targeting commercial markets for INBRIJA in Latin America and is in discussions for rights in other European countries.
